Impact of low-dose irradiation and in vivo T-cell depletion on hematopoietic stem cell transplantation for non-malignant diseases using fludarabine-based reduced-intensity conditioning.
Adolescent
Adult
Aged
Antineoplastic Agents
/ pharmacology
Child
Child, Preschool
Female
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Infant
Infant, Newborn
Lymphocyte Depletion
/ methods
Male
Middle Aged
Transplantation Conditioning
/ methods
Vidarabine
/ analogs & derivatives
Young Adult
Journal
Bone marrow transplantation
ISSN: 1476-5365
Titre abrégé: Bone Marrow Transplant
Pays: England
ID NLM: 8702459
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
20
08
2018
accepted:
10
11
2018
revised:
16
10
2018
pubmed:
12
12
2018
medline:
13
8
2020
entrez:
12
12
2018
Statut:
ppublish
Résumé
Reduced-intensity conditioning is widely used with hematopoietic stem cell transplantation for non-malignant diseases: however, the optimal conditioning to ensure stable engraftment has not been established. In this study, we retrospectively compared the impact of low-dose (1-6 Gy) irradiation and in vivo T-cell depletion on the clinical outcome of 523 patients with non-malignant disease who underwent a first allogeneic hematopoietic stem cell transplantation using fludarabine-based reduced-intensity conditioning. Use of low-dose irradiation, but not of anti-thymocyte globulin/anti-lymphocyte globulin, showed a beneficial effect on overall survival (adjusted hazard ratio: 0.56; 95% confidence interval: 0.35-0.91, P = 0.018). Furthermore, use of low-dose irradiation was strongly associated with lower transplant-related mortality (adjusted hazard ratio: 0.55; 95% confidence interval: 0.32-0.96, P = 0.034). The addition of low-dose irradiation to the conditioning regimen was beneficial, at least to the short-term clinical outcome. A large prospective study with long-term follow-up is now required to extend these findings and establish the optimal hematopoietic stem cell transplant conditioning for patients with at least some subgroups of non-malignant diseases.
Identifiants
pubmed: 30531957
doi: 10.1038/s41409-018-0418-8
pii: 10.1038/s41409-018-0418-8
doi:
Substances chimiques
Antineoplastic Agents
0
Vidarabine
FA2DM6879K
fludarabine
P2K93U8740
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM